Navigation Links
Syneron Medical Completes and Summarizes the Multi-site Clinical Study Agreed Upon with FDA for the UltraShape Contour I
Date:10/21/2013

IRVINE, California, October 21, 2013 /PRNewswire/ --

Syneron Medical Ltd. (NASDAQ: ELOS), a global market leader in the aesthetic medical device marketplace, announced that it has completed the multi-site clinical study for the UltraShape Contour I System for non-invasive abdominal circumferential reduction.

     (Logo: http://photos.prnewswire.com/prnh/20120528/535447)

The Contour I is designed to use the mechanical effects of ultrasound to disrupt fat cells non-invasively. It achieves this effect without any significant heating of the target or adjacent tissue, minimizing any impact on blood vessels, nerves, and muscle tissue outside the target area. The Contour I also provides an automatic guidance system that adjusts for patient movement for enhanced user convenience and for a high degree of safety.  

In the randomized, controlled clinical study of the Contour I, which was performed in 3 clinical sites in the U.S. and one site outside the U.S., a total of 150 subjects were treated and followed-up for up to 4 months. In this multi-site study, an average abdominal circumference reduction of 2.4-3.5 cm was demonstrated. The results successfully met the primary hypothesis for clinically significant circumference reduction. Furthermore, the results demonstrated progressive improvement over time in circumference reduction, beginning after the first treatment session. No serious adverse events related to the device were reported. The treatment was administered without the need for anesthetic and was well tolerated by patients.

The Contour I received the CE mark in 2005 and is marketed in European countries, Canada, Australia, Israel, Mexico, Brazil, Urugua
'/>"/>

SOURCE Syneron Medical Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Global Medical Imaging Reagents Market 2012 - 2016: Worldwide Industry Latest Market Share, Investment Trends, Growth, Size, Trends, Strategy And Forecast Research Report
2. Cedars-Sinai Medical Center to Use Exosome Diagnostics Exosome RNA Biofluid Kits in Neo-Natal Setting and Cancer for Development of Personalized Medicine Diagnostics
3. Dr. Szczepan Baran Appointed to Board of Directors at Americans for Medical Progress
4. Global Medical Experts to Discuss Knowledge Translation for Integration of Complementary Therapies in Cancer Treatment at Vancouver, BC Conference
5. Global 3D Medical Imaging Industry
6. Portland Medical Marijuana Clinic - The Aurora Clinic - Now Offering Complimentary Telephone Consultations for Washington and Oregon Medical Marijuana Cards
7. V. Suzanne Klimberg, M.D. Appointed Medical Director of Ascendant Diagnostics™
8. Miami’s Preferred Cord Blood Laboratory, GeneCell International, Partakes in North Shore Medical Center and Hialeah Hospital’s OB/GYN Symposium
9. Young scientists receive NSBRI space biomedical research fellowships
10. Avon Foundation for Women, NIH, and the Center for Advancing Innovation Launch Start-Up Challenge to Advance Breast Cancer Biomedical Invention
11. VIVEX BIOMEDICAL Successfully Completes $7.6 Million Round of Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... PLEASANTON, Calif. , Dec. 19, 2014  Roche ... acquisition of Bina Technologies, Inc. (Bina), a privately ... California , USA. Bina provides a big ... next generation sequencing (NGS) data. Bina,s proprietary on-market ... translational and academic researchers to perform fast and ...
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources Group ... grow at a 12 percent compound annual growth rate ... the aging population and the increasing adoption of dental ... will also spur demand for dental biomaterials ... implant and periodontal treatments. Other key findings ...
(Date:12/19/2014)... 18, 2014 BioPlus Specialty ... specialty pharmacies, has an expanded team of Regional ... consultants for prescriber offices in their regions, with ... “We have a variety of Regional Pharmaceutical Care ... specializing in hepatitis C help prescribers understand all ...
(Date:12/19/2014)... LayerBio is an MIT spin-off developing ... The National Eye Institute (NEI) at the National Institutes ... SBIR grant to develop a drug-eluting intraocular lens (IOL) ... cause of vision loss in people over age 40 ... Dr. Ken Mandell, LayerBio’s Founder and CEO, "There is ...
Breaking Biology Technology:Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
... call "hostile-environment technology." These are the machines, devices and ... are dangerous or impossible for humans to tread. Like ... reactor facilities. Two Arizona State University electrical engineers ... generation of these technologies, supported by a recent $1.7 ...
... BRNO, Czech Republic, November 16, 2011 ... provides complete diagnostics, treatment, and preventive care in ... MMCI is the only health care provider in ... the OECI (Organisation of European Cancer Institutes). ...
... Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company ... today announced top-line data from its recently completed ... pharmacodynamics (PD), safety and tolerability of subcutaneous bolus ... chronic heart failure. Nile is developing cenderitide as ...
Cached Biology Technology:Arizona State University engineers aim to improve performance of technology in extreme environments 2Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS 2Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS 3Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint 2Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint 3Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint 4
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
(Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... analysis has found that many doctors report that they ... and testing services to their female patients. Published early ... the American Cancer Society, the study indicates that efforts ... and discourage them for average-risk women. Women with ...
... association study published in the August issue of ... that can predict which patients with Hodgkin,s lymphoma are ... treatment. Knowing in advance who is at risk could ... patients who are most susceptible to long-term damage. ...
... target for nitric oxide has been revealed in studies of how ... cause of food-poisoning. "Nitric oxide is naturally produced ... body to ward off infection," explained the senior author of the ... professor of laboratory medicine, microbiology and medicine. Nitric oxide ...
Cached Biology News:Mismatch between cancer genetics counseling and testing guidelines and physician practices 22 genetic variations predict second cancers after radiation for children with Hodgkin lymphoma 22 genetic variations predict second cancers after radiation for children with Hodgkin lymphoma 3New target found for nitric oxide's attack on salmonella bacteria 2New target found for nitric oxide's attack on salmonella bacteria 3
... Chicken polyclonal to LYZL6 ( Abpromise ... Antigen: Synthetic peptide: ... HVDCQD , corresponding to amino acids ... Entrez Gene ID: 57151 ...
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
Mouse Anti-Lamin B...
Biology Products: